Nutritional and Botanical Approaches for Inflammatory Bowel Disease

Alatab S , Sepanlou SG , Ikuta K , et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol, 2020; 5:17–30.

Dahlhamer JM , Zammitti EP , Ward BW , et al. Prevalence of inflammatory bowel disease among adults aged ≥18 years—United States, 2015. MMWR Morb Mortal Wkly Rep, 2016; 65:1166–1169.

Nguyen GC , Chong CA , Chong RY . National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States. J Crohns Colitis, 2014; 8:288–295.

Kaplan GG , Ng SC . Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology, 2017; 152:313–321.e2.

M'Koma AE. Inflammatory bowel disease: An expanding global health problem. Clin Med Insights Gastroenterol, 2013; 6:33–47.

Wen Z , Fiocchi C. Inflammatory bowel disease: Autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004;11:195–204.

Guarner F. What is the role of the enteric commensal flora in IBD?. Inflamm Bowel Dis, 2008; 14:S83–S84.

Rogler G , Zeitz J , Biedermann L . The search for causative environmental factors in inflammatory bowel disease. Dig Dis, 2016; 34:48–55.

Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol, 2015; 12:205–217.

Owczarek D , Rodacki T , Domagała-Rodacka R , et al. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol, 2016; 22:895–905.

Andersen V , Olsen A , Carbonnel F , et al. Diet and risk of inflammatory bowel disease. Dig Liver Dis, 2012; 44:185–194.

Habibi F , Habibi ME , Gharavinia A , et al. Quality of life in inflammatory bowel disease patients: A cross-sectional study. J Res Med Sci, 2017; 22:104.

Van der Have M , van der Aalst KS , Kaptein AA , et al. Determinants of health-related quality of life in Crohn's disease: A systematic review and meta-analysis. J Crohns Colitis, 2014; 8:93–106.

Cerrillo E , González ES , Bastida G , et al. Extraintestinal manifestations in inflammatory bowel disease. Med, 2020; 13:618–630.

Waugh N , Cummins E , Royle P , et al. Faecal Calprotectin Testing for Differentiating Amongst Inflammatory and Non-inflammatory Bowel Diseases: Systematic Review and Economic Evaluation. NIHR Journals Library. Southampton, UK, 2013.

Pittayanon R , Lau JT , Leontiadis GI , et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: A systematic review. Gastroenterology, 2020; 158:930–946.e1.

Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res, 2019; 12:7247238.

Nemeth ZH , Bogdanovski DA , Barratt-Stopper P , et al. Crohn's disease and ulcerative colitis show unique cytokine profiles. Cureus, 2017; 9:e1177.

Best WR , Becktel JM , Singleton JW , et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology, 1976; 70:439–444.

Jowett SL , Seal CJ , Barton JR , et al. The Short Inflammatory Bowel Disease Questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol, 2001; 96:2921–2928.

Halfvarson J , Brislawn CJ , Lamendella R , et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol, 2017; 2:17004.

Kostic AD , Xavier RJ , Gevers D . The microbiome in inflammatory bowel disease: Current status and the future ahead. Gastroenterology, 2014; 146:1489–1499.

Aleksandrova K , Romero-Mosquera B , Hernandez V . Diet, gut microbiome and epigenetics: Emerging links with inflammatory bowel diseases and prospects for management and prevention. Nutrients, 2017; 9:1–13.

Lam S , Zuo T , Ho M , et al. Review article: Fungal alterations in inflammatory bowel diseases. Aliment Pharmacol Ther, 2019; 50:1159–1171.

Astó E , Méndez I , Audivert S , et al. The efficacy of probiotics, prebiotic inulin-type fructans, and synbiotics in human ulcerative colitis: A systematic review and meta-analysis. Nutrients, 2019; 11:293.

Derwa Y , Gracie DJ , Hamlin PJ , et al. Systematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther, 2017; 46:389–400.

Colman RJ , Rubin DT . Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis. J Crohn's Colitis, 2014; 8:1569–1581.

Moayyedi P , Surette MG , Kim PT , et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology, 2015; 149:102–109.e6.

Rossen NG , Fuentes S , Van Der Spek MJ , et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology, 2015; 149:110–118.e4.

Levy AN , Allegretti JR . Insights into the role of fecal microbiota transplantation for the treatment of inflammatory bowel disease. Therap Adv Gastroenterol, 2019; 12:1756284819836893.

Paramsothy S , Paramsothy R , Rubin DT , et al. Faecal microbiota transplantation for inflammatory bowel disease: A systematic review and meta-analysis. J Crohn's Colitis, 2017; 11:1180–1199.

Karatzas PS , Gazouli M , Safioleas M , et al. DNA methylation changes in inflammatory bowel disease. Ann Gastroenterol, 2014; 27:125–132.

Zoli G , Care M , Parazza M , et al. A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease. Aliment Pharmacol Ther, 1997; 11:735–740.

Morain CO , Segal AW , Levi AJ . Elemental diet as primary treatment of acute Crohn's disease: A controlled trial. Br Med J, 1984; 288:1859–1862.

Popa SL , Pop C , Dumitrascu DL . Diet advice for Crohn's disease: FODMAP and beyond. Nutrients, 2020; 12:3751.

Konijeti GG , Kim N , Lewis JD , et al. Efficacy of the autoimmune protocol diet for inflammatory bowel disease. Inflamm Bowel Dis, 2017; 23:2054–2060.

Gunasekeera V , Mendall MA , Chan D , et al. Treatment of Crohn's disease with an IgG4-guided exclusion diet: A randomized controlled trial. Dig Dis Sci, 2016; 61:1148–1157.

Larsen PM , Rasmussen D , Rønn B , et al. Elemental diet: A therapeutic approach in chronic inflammatory bowel disease. J Intern Med, 1989; 225:325–331.

Muir JG , Gibson PR . The low FODMAP diet for treatment of irritable bowel syndrome and other gastrointestinal disorders. Gastroenterol Hepatol, 2013; 9:450–452.

Srinath AI , Walter C , Newara MC , et al. Pain management in patients with inflammatory bowel disease: Insights for the clinician. Therap Adv Gastroenterol, 2012; 5:339–357.

Bischoff SC , Escher J , Ebuterne XH , et al. ESPEN Guideline ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. Clin Nutr, 2020; 39:632–653.

Brinker AM , Ma J , Lipsky PE , et al. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry, 2007; 68:732–766.

Ren J , Tao Q , Wang X , et al. Efficacy of T2 in active Crohn's disease: A prospective study report. Dig Dis Sci, 2007; 52:1790–1797.

Gong J , Niu L , Wei X , et al. Study on the effect of enteral nutrition combined with Tripterygium wilfordii polyglycosides to induce Crohn's disease. Chinese J Surg, 2009; 47:1213–1217.

Ren J , Wu X , Liao N , et al. Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. J Int Med Res, 2013; 41:176–187.

Tao QS , Ren JA , Ji ZL , et al. [Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. Chin J Gastrointest Surg, 2009; 12:491–493.

Liao N-S , Ren J-An , Fan C-G , et al. Efficacy of polyglycosides of Tripterygium wilfordii in preventing postoperative recurrence of Crohn disease. Zhonghua Wei Chang Wai Ke Za Zhi, 2009; 12:167–169.

Zhu W , Li Y , Gong J , et al. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: A randomized clinical trial. Dig Liver Dis, 2015; 47:14–19.

Sun J , Shen X , Dong J , et al. Tripterygium wilfordii hook F as maintenance treatment for Crohn's disease. Am J Med Sci, 2015; 350:345–351.

Ru Y , Luo Y , Zhou Y , et al. Adverse events associated with treatment of Tripterygium wilfordii Hook F: A quantitative evidence synthesis. Front Pharmacol, 2019; 10:1250.

Zhang C , Sun PP , Guo HT , et al. Safety profiles of Tripterygium wilfordii Hook F: A systematic review and meta-analysis. Front Pharmacol, 2016; 7:402.

Jayakumar T , Hsieh CY , Lee JJ , et al. Experimental and clinical pharmacology of Andrographis paniculata and its major bioactive phytoconstituent andrographolide. Evid Based Complement Altern Med, 2013; 2013:846740.

Michelsen KS , Wong MH , Ko B , et al. HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and T H 1/T H 17 responses. Inflamm Bowel Dis, 2013; 19:151–164.

Tang T , Targan SR , Li ZS , et al. Randomised clinical trial: Herbal extract HMPL-004 in active ulcerative colitis—A double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther, 2011; 33:194–202.

Sandborn WJ , Targan SR , Byers VS , et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol, 2013; 108:90–98.

Langmead L , Feakins RM , Goldthorpe S , et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther, 2004; 19:739–747.

Holt PR , Katz S , Kirshoff R . Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci, 2005; 50:2191–2193.

Zheng T , Wang X , Chen Z , et al. Efficacy of adjuvant curcumin therapy in ulcerative colitis: A meta-analysis of randomized controlled trials. J Gastroenterol Hepatol, 2020; 35:722–729.

Hanai H , Iida T , Takeuchi K , et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol, 2006; 4:1502–1506.

Suskind DL , Wahbeh G , Burpee T , et al. Tolerability of curcumin in pediatric inflammatory bowel disease: A forced-dose titration study. J Pediatr Gastroenterol Nutr, 2013; 56:277–279.

Dimas K , Pantazis P , Ramanujam R . Review: Chios mastic gum: a plant-produced resin exhibiting numerous diverse pharmaceutical and biomedical properties. In Vivo (Brooklyn), 2012; 26:777–785.

Kaliora AC , Stathopoulou MG , Triantafillidis JK , et al. Chios mastic treatment of patients with active Crohn's disease. World J Gastroenterol, 2007; 13:748–753.

Papada E , Gioxari A , Amerikanou C , et al. Regulation of faecal biomarkers in inflammatory bowel disease patients treated with oral mastiha (Pistacia lentiscus) supplement: A double-blind and placebo-controlled randomised trial. Phyther Res, 2019; 33:360–369.

Szopa A , Pajor J , Klin P , et al. Artemisia absinthium L.—Importance in the history of medicine, the latest advances in phytochemistry and therapeutical, cosmetological and culinary uses. Plants, 2020; 9:1063.

Algieri F , Rodriguez-Nogales A , Rodriguez-Cabezas ME , et al. Botanical drugs as an emerging strategy in inflammatory bowel disease: A review. Mediators Inflamm, 2015; 2015:179616.

Krebs S , Omer TN , Omer B . Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease—A controlled clinical trial. Phytomedicine, 2010; 17:305–309.

Omer B , Krebs S , Omer H , et al. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: A double-blind placebo-controlled study. Phytomedicine, 2007; 14:87–95.

Picardo S , Kaplan GG , Sharkey KA , et al. Insights into the role of cannabis in the management of inflammatory bowel disease. Therap Adv Gastroenterol, 2019; 12:1756284819870977.

Lal S , Prasad N , Ryan M , et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol, 2011; 23:891–896.

Naftali T , Bar-Lev Schleider L , Dotan I , et al. Cannabis induces a clinical response in patients with Crohn's disease: A prospective placebo-controlled study. Clin Gastroenterol Hepatol, 2013; 11:1276–1280.

Naftali T , Bar Lev L , Yablekovitz D , et al. Treatment of Crohn's disease with cannabis: An observational study. Isr Med Assoc J, 2011; 13:455–458.

Naftali T , Mechulam R , Marii A , et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn's disease, a randomized controlled trial. Dig Dis Sci, 2017; 62:1615–1620.